Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that Michael Cola has stepped down as Chief Executive Officer effective immediately at the request of the Board. Co-founder and Executive Chairman Eric So has been appointed as Interim CEO while a search for a permanent successor is underway. The leadership transition is intended to ensure continuity as the company advances its clinical pipeline, including the anticipated fourth-quarter topline data readout from the APPROACH trial of HLP003, while maintaining focus on long-term value creation for patients and shareholders.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. HLP003, a proprietary NSA, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs.
Eric So, co-founder and executive chairman, brings deep knowledge of the company’s strategic vision and pipeline. His appointment as interim CEO provides stability during the search for a permanent leader. The company operates in Canada, the United States, the United Kingdom, and Ireland. For further details, the full press release can be viewed at https://ibn.fm/3Gp8X. Company updates and more information about Helus Pharma are available at www.helus.com. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
